SpringWorks Therapeutics Inc. (SWTX) – Hot Comments
-
UPDATE: Spring Works Therapeutics (SWTX) PT Lowered to $50 at Wedbush
-
JPMorgan Reiterates $92 PT on Spring Works Therapeutics (SWTX), 'we continue to see underappreciated fundamental value with nirogacestat in desmoid tumors and BCMA programs'
Back to SWTX Stock Lookup